In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."
The latest from The Motley Fool's biotech show "Biotech Banter."
Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Intuitive Surgical (ISRG) Q1 2024 Earnings Call Transcript
Why Ultra-High-Yield Dividend Stock Medical Properties Trust Is Skyrocketing This Week
Medtronic Stock: Buy, Sell, or Hold?
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
644%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.